 Acasti Pharma Incs NASDAQ: ACST pharmacokinetic PK bridging study with IV GTX-104, its lead drug candidate for Subarachnoid Hemorrhage SAH, met all its planned study endpoints. The studys primary objective was to evaluate the relative bioavailability of IV GTX-104. 